AlphaVax is launching clinical trials of vaccines designed to fight cytomegalovirus (CMV) and influenza.

Funded in part by the National Institutes for Health, the vaccines are based on proprietary technology developed by AlphaVax.

CMV is the most common infection found in children at birth in the United States, according to the Centers for Disease Control. CMV is part of the herpesvirus family, which includes the herpes viruses and viruses that cause chicken pox. CMV can cause disease in unborn babies and in people who have a weakened immune system.

The influenza vaccine is being developed as a potential counter to a pandemic outbreak.

In the first trials, healthy humans are receiving the vaccines.

“CMV and influenza are two diseases of major public health importance,"
said Dr. Jeff Chulay, AlphaVax’s chief medical officer. "These clinical
trials are an important step towards delivering products based on our
vaccine technology to those who can benefit from them."